Publication List 1995

1984-94, 1995, 1996, 1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022

18
（111）		 Colosetti P, Olsson T, Miyazono K, Funa K.
Axotomy of rat facial nerve induces TGF-β and latent TGF-β binding protein.
Brain Res Bull. 1995;37(6):561-7.
17
（110）		 Olofsson A, Ichijo H, Morén A, ten Dijke P, Miyazono K, Heldin CH.
Efficient association of an amino-terminally extended form of human latent transforming growth factor-β binding protein with the extracellular matrix.
J Biol Chem. 1995 Dec 29;270(52):31294-7.
16
（109）		 Kawabata M, Imamura T, Miyazono K, Engel ME, Moses HL.
Interaction of the transforming growth factor-β type I receptor with farnesyl-protein transferase-α.
J Biol Chem. 1995 Dec 15;270(50):29628-31.
15
（108）		 Ishidou Y, Kitajima I, Obama H, Maruyama I, Murata F, Imamura T, Yamada N, ten Dijke P, Miyazono K, Sakou T.
Enhanced expression of type I receptors for bone morphogenetic proteins during bone formation.
J Bone Miner Res. 1995 Nov;10(11):1651-9.
14
（107）		 Dallas SL, Miyazono K, Skerry TM, Mundy GR, Bonewald LF.
Dual role for the latent transforming growth factor-β binding protein in storage of latent TGF-β in the extracellular matrix and as a structural matrix protein.
J Cell Biol. 1995 Oct;131(2):539-49.
13
（106）		 Iseki S, Osumi-Yamashita N, Miyazono K, Franzén P, Ichijo H, Ohtani H, Hayashi Y, Eto K.
Localization of transforming growth factor-β type I and type II receptors in mouse development.
Exp Cell Res. 1995 Aug;219(2):339-47.
12
（105）		 Henriksen R, Gobl A, Wilander E, Oberg K, Miyazono K, Funa K.
Expression and prognostic significance of TGF-β isotypes, latent TGF-β1 binding protein, TGF-β type I and type II receptors, and endoglin in normal ovary and ovarian neoplasms.
Lab Invest. 1995 Aug;73(2):213-20.
11
（104）		 Rosenzweig BL, Imamura T, Okadome T, Cox GN, Yamashita H, ten Dijke P, Heldin CH, Miyazono K.
Cloning and characterization of a human type II receptor for bone morphogenetic proteins.
Proc Natl Acad Sci U S A. 1995 Aug 15;92(17):7632-6.
10
（103）		 Yamada N, Kato M, Yamashita H, Nistér M, Miyazono K, Heldin CH, Funa K.
Enhanced expression of transforming growth factor-β and its type-I and type-II receptors in human glioblastoma.
Int J Cancer. 1995 Aug 9;62(4):386-92.
9
（102）		 Yamashita H, ten Dijke P, Huylebroeck D, Sampath TK, Andries M, Smith JC, Heldin CH, Miyazono K.
Osteogenic protein-1 binds to activin type II receptors and induces certain activin-like effects.
J Cell Biol. 1995 Jul;130(1):217-26.
8
（101）		 Verschueren K, Dewulf N, Goumans MJ, Lonnoy O, Feijen A, Grimsby S, Vandi Spiegle K, ten Dijke P, Morén A, Vanscheeuwijck P, Heldin CH, Miyazono K, Mummery C, Van Den Eijnden-Van Raaij J, Huylebroeck D.
Expression of type I and type IB receptors for activin in midgestation mouse embryos suggests distinct functions in organogenesis.
Mech Dev. 1995 Jul;52(1):109-23.
7
（100）		 Tamaki K, Okuda S, Miyazono K, Nakayama M, Fujishima M.
Matrix-associated latent TGF-β with latent TGF-β binding protein in the progressive process in adriamycin-induced nephropathy.
Lab Invest. 1995 Jul;73(1):81-9.
6
（99）		 van Laethem JL, Deviere J, Resibois A, Rickaert F, Vertongen P, Ohtani H, Cremer M, Miyazono K, Robberecht P.
Localization of transforming growth factor β1 and its latent binding protein in human chronic pancreatitis.
Gastroenterology. 1995 Jun;108(6):1873-81.
5
（98）		 Dewulf N, Verschueren K, Lonnoy O, Morén A, Grimsby S, Vande Spiegle K, Miyazono K, Huylebroeck D, Ten Dijke P.
Distinct spatial and temporal expression patterns of two type I receptors for bone morphogenetic proteins during mouse embryogenesis.
Endocrinology. 1995 Jun;136(6):2652-63.
4
（97）		 Kato M, Ishizaki A, Hellman U, Wernstedt C, Kyogoku M, Miyazono K, Heldin CH, Funa K.
A human keratinocyte cell line produces two autocrine growth inhibitors, transforming growth factor-β and insulin-like growth factor binding protein-6, in a calcium- and cell density-dependent manner.
J Biol Chem. 1995 May 26;270(21):12373-9.
3
（96）		 Heldin CH, Miyazono K.
[Transforming growth factor-β. An interesting candidate for clinical use].
Lakartidningen. 1995 Apr 12;92(15):1569-72.
2
（95）		 Franzén P, Heldin CH, Miyazono K.
The GS domain of the transforming growth factor-β type I receptor is important in signal transduction.
Biochem Biophys Res Commun. 1995 Feb 15;207(2):682-9.
1
（94）		 Yamashita H, Okadome T, Franzén P, ten Dijke P, Heldin CH, Miyazono K.
A rat pituitary tumor cell line (GH3) expresses type I and type II receptors and other cell surface binding protein(s) for transforming growth factor-β.
J Biol Chem. 1995 Jan 13;270(2):770-4.